Aptose Biosciences Inc. Reports Q2 2023 Net Loss of $14.1 Million

Aptose Biosciences Inc.(APTO), a biotechnology company focus ed on developing innovative therapeutics, has released its Condensed Consolidated Interim Financial Statements for the second quarter of 2023. The financial report reveals a net loss of $14.1 million for the quarter, and the company reported no revenue during the period. The financial data indicates the company's current financial position, including its assets, liabilities, and shareholders' equity.

Financial Position: Assets and Liabilities

Aptose Biosciences Inc. reported total assets of $26.6 million as of June 30, 2023, compared to $51.0 million as of December 31, 2022. The company's assets include cash and cash equivalents of $8.4 million, investments totaling $14.9 million, and prepaid expenses of $1.7 million. Current assets decreased from $49.5 million at the end of 2022 to $25.3 million in the second quarter of 2023.

On the liability side, the company reported total liabilities of $12.8 million as of June 30, 2023, compared to $13.3 million at the end of 2022. Current liabilities include accounts payable of $3.5 million, accrued liabilities of $8.1 million, and current portion of lease liability of $387 thousand.